Current therapy and drug resistance in metastatic castration-resistant prostate cancer
出版年份 2023 全文链接
标题
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
作者
关键词
-
出版物
DRUG RESISTANCE UPDATES
Volume 68, Issue -, Pages 100962
出版商
Elsevier BV
发表日期
2023-04-14
DOI
10.1016/j.drup.2023.100962
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
- (2022) Maha Hussain et al. CLINICAL CANCER RESEARCH
- Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
- (2022) Evan Y. Yu et al. EUROPEAN UROLOGY
- Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial
- (2022) Fred Saad et al. LANCET ONCOLOGY
- CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling
- (2022) Tao Xie et al. Molecular Cancer
- A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance
- (2022) J. Kellogg Parsons et al. European Urology Focus
- Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
- (2021) Veronica Mollica et al. Cancers
- Cross-resistance and drug sequence in prostate cancer
- (2021) Stefan A.J. Buck et al. DRUG RESISTANCE UPDATES
- Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
- (2021) Marzieh Ehsani et al. Cancers
- Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
- (2021) Vicenç Ruiz de Porras et al. CANCER LETTERS
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Christopher Sweeney et al. LANCET
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
- (2020) Yukiyoshi Hirayama et al. Molecular Oncology
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer
- (2019) Scott T. Tagawa et al. CANCER
- The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells
- (2019) Claudia Tanja Mierke REPORTS ON PROGRESS IN PHYSICS
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
- (2018) Heini M. L. Kallio et al. BRITISH JOURNAL OF CANCER
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- The challenge of drug resistance in cancer treatment: a current overview
- (2018) Michail Nikolaou et al. CLINICAL & EXPERIMENTAL METASTASIS
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Interference with the androgen receptor protein stability in therapy-resistant prostate cancer
- (2018) Gopinath Lakshmana et al. INTERNATIONAL JOURNAL OF CANCER
- Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
- (2018) Min Yuen Teo et al. BRITISH JOURNAL OF CANCER
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
- (2017) Matthew R. Smith et al. EUROPEAN UROLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
- (2017) Min Zou et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Impact of the physical microenvironment on tumor progression and metastasis
- (2016) Fabian Spill et al. CURRENT OPINION IN BIOTECHNOLOGY
- BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
- (2016) Rinske Drost et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation
- (2016) Hongli Liu et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both
- (2016) Nicholas D. James et al. JAMA Oncology
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
- (2015) Shalu Pahuja et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- (2015) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- Targeting the glucocorticoid receptor in breast and prostate cancers
- (2015) Jacob Kach et al. Science Translational Medicine
- CYP17A1 inhibitors in castration-resistant prostate cancer
- (2015) Lissette Gomez et al. STEROIDS
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure
- (2015) Thea Grindstad et al. PLoS One
- Characterisation of human prostate epithelial progenitor differentiation in response to androgens
- (2015) R Heer ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND
- The pharmacological point of view of resistance to therapy in tumors
- (2014) Giovanna Damia et al. CANCER TREATMENT REVIEWS
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Nanoways to overcome docetaxel resistance in prostate cancer
- (2014) Aditya Ganju et al. DRUG RESISTANCE UPDATES
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- “Drug resistance associated membrane proteinsâ€
- (2014) Katy S. Sherlach et al. Frontiers in Physiology
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Overview of the latest treatments for castration-resistant prostate cancer
- (2013) Mohamed Bishr et al. Nature Reviews Urology
- Long non-coding RNAs and human disease
- (2012) Lorna W. Harries BIOCHEMICAL SOCIETY TRANSACTIONS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Tumour evolution inferred by single-cell sequencing
- (2011) Nicholas Navin et al. NATURE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advancing a clinically relevant perspective of the clonal nature of cancer
- (2011) C. Ruiz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study
- (2011) Orazio Caffo et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- MacroRNA underdogs in a microRNA world: Evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA
- (2010) Leonard Lipovich et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients
- (2010) S Crnalic et al. ENDOCRINE-RELATED CANCER
- Drug resistance in metastatic castration-resistant prostate cancer
- (2010) Bostjan Seruga et al. Nature Reviews Clinical Oncology
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
- (2009) N. M. Hahn et al. ANNALS OF ONCOLOGY
- Increased expression of class III β-tubulin in castration-resistant human prostate cancer
- (2009) S Terry et al. BRITISH JOURNAL OF CANCER
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now